<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035876</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-SHR-APA-ZJU</org_study_id>
    <nct_id>NCT04035876</nct_id>
  </id_info>
  <brief_title>Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant</brief_title>
  <official_title>A Single Group, Open Label, Multi-center Clinical Study of Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of Hepatocellular Cancer Before Liver Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shulan (Hangzhou) Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for
      downstaging/bridging of HCC before liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCC patients waiting for liver transplantation will be screened and enrolled according to the
      inclusion criteria. After screening and enrollment, patients will be administrated
      camrelizumab 200mg q2w iv and apatinib 250mg qd po regimen every 4 weeks as a cycle. Each
      patient will receive camrelizumab treatment for at least 2 cycles and discontinue
      camrelizumab 5 weeks before liver transplantation. Apatinib will be discontinued 1 week
      before liver transplantation. Once the tumor progression was detected, the program will be
      terminated and the appropriate optimal treatment will be given. The objective remission rate
      (ORR), recurrence-free survival (RFS), overall survival (OS), time to progress (TTP) and any
      adverse effect during the study will be evaluated in order to assess the primary effects and
      safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 16, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective remission rate</measure>
    <time_frame>From enrollment to disease progression, up to 6 months</time_frame>
    <description>The proportion of patients with CR, PR, and SD in the group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>The period from enrollment surgery to recurrence of HCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>The survival rate in a year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progress</measure>
    <time_frame>From enrollment to disease progression, up to 6 months</time_frame>
    <description>The period from enrollment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>1 year</time_frame>
    <description>Any adverse effects occur during the project</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Camrelizumab plus apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab plus apatinib</intervention_name>
    <description>Camrelizumab 200mg q2w iv and apatinib 250mg qd po.</description>
    <arm_group_label>Camrelizumab plus apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years

          -  Pathology: hepatocellular carcinoma

          -  Exceed Hangzhou Criteria (Type A: diameter of tumor ≤ 8 cm or diameter of tumor and
             AFP ≤ 100 ng/mL; Type B: diameter of tumor &gt;8 cm, but 100 ng/mL &lt; AFP &lt;400 ng/mL)

          -  No interventional therapy (TACE, RFA or I131) within 2 month

          -  Expected survival for more than 3 months

          -  Child-pugh grade A or grade B (≤ 7 points)

          -  Absolute neutrophil count ≥ 1.5×10^9 /L, Hb ≥ 9 g/L, PLT ≥ 100×10^9 /L; TSH ≤ ULN;
             total bilirubin ≤ 1.5 ULN, albumin ≥ 28 g/L, AST, ALT ≤ 3 ULN; serum creatinine ≤ 1.5
             ULN

          -  ECOG: 0-2

          -  Patients participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Regional lymph node metastases or extrahepatic metastases

          -  Allergic to Camrelizumab or Apatinib

          -  Patients who have had or are currently complicated with other malignant tumors

          -  Active hepatitis (hepatitis B: HBsAg positive or HBV- DNA≥10⁴copies/ml; hepatitis C:
             HCV antibodies and HCV-RNA positive)

          -  Activ pulmonary tuberculosis or pulmonary tuberculosis history

          -  Active, diagnosed, or suspected autoimmune disease (including but not limited to:
             uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism,
             hypothyroidism and asthma)

          -  Interstitial lung disease history or non-infectious pneumonia requiring oral or
             intravenous steroid therapy

          -  Long-term systemic hormone therapy (dose &gt; 10mg prednisone/day) or any other form of
             immunosuppressive therapy

          -  Myocardial ischemia or myocardial infarction above grade II, hypertension and
             inability to reach the normal range after medication (systolic blood pressure
             &gt;140mmHg, diastolic blood pressure &gt;90mmHg)

          -  Abnormal coagulation function (PT&gt;16s, APTT&gt;43s, TT&gt;21s, Fbg&lt;2g/L); history of
             gastrointestinal bleeding within 6 months; obvious bleeding tendency or undergoing
             thrombolytic or anticoagulant treatment

          -  Pregnant or lactating women

          -  Patients who participated in other clinical trials within 1 month

          -  Active infections which require systemic treatment

          -  HIV positive

          -  Other factors that may affect patients' safety or compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianguo Wang, PhD</last_name>
    <phone>(+86)15967123327</phone>
    <email>21118059@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianguo Wang, PhD</last_name>
      <phone>(+86)15967123327</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Xiao Xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Camrelizumab</keyword>
  <keyword>Apatinib</keyword>
  <keyword>HCC</keyword>
  <keyword>Liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

